Immunglobulin M Enriched Intra Venous Immunoglobulin (IVIG) Therapy in Adult Respiratory Distress Syndrom (ARDS) Patients

University Hospital Tuebingen

Status: Completed

Conditions: Respiratory Distress Syndrome, Adult; Septic Shock

Treatments: Drug: IgM enriched Immunoglobulins

Study type: Observational

Funder types: Other

Identifiers

NCT02961166

University Hospital Tuebingen

Details and patient eligibility

About

57 patients with Adult Respiratory Distress Syndrome (ARDS) requiring Extracorporeal membrane oxygenation (ECMO) therapy were analyzed retrospectively. 28 patients had received immunglobulin M-enriched immunoglobulin therapy (IVIG); 29 patients did not receive IVIG therapy.

These patients were analyzed regarding length of stay in intensive care unit (LOS ICU), length of stay (LOS) in hospital and regarding mortality.

Full description

57 patients with ARDS requiring ECMO therapy were analyzed retrospectively. 28 patients had received IgM-enriched immunoglobulin therapy (IVIG); 29 patients did not receive IVIG therapy.

Patient characteristics, like Acute Physiology And Chronic Health Evaluation (APACHE) and Sepsis-related organ failure assessment (SAPS) Score, preexisting diseases, origin of infection, duration of ECMO therapy were analyzed in these patients.

These patients were further analyzed regarding LOS ICU, LOS in hospital and regarding mortality.

Enrollment: 57 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• All data available
• ARDS with ECMO therapy

Exclusion criteria

• Data missing

Trial design

57 participants in 2 patient groups

IgM enriched Immunoglobulins

Description:

ARDS patients with septic shock requiring ECMO therapy were treated for 3 days by IgM-enriched Immunoglobulin

Treatment:

Drug: IgM enriched Immunoglobulins

Control

Description:

ARDS patients with septic shock requiring ECMO therapy were NOT treated by IgM-enriched Immunoglobulin